(CNN)French pharmaceutical giant Sanofi SA paused development of a Zika virus vaccine ... This Pennsylvania-based company recently completed a public offering of common stock to support various projects, including publication in the …
CNN2mon
the FDA sent the company an "approvable letter," meaning that it needed to run more tests before getting a green light. Salares does not own Sanofi stock. Leerink Swann does not do business with the company and does not cover it …
And this is why Sanofi stock is plummeting. In that market, “sudden prices declines like this are unexpected,” writes Sanford Bernstein analyst Tim Anderson. “This is bad. Because it is price that Sanofi is giving up.”
The company said it plans to buy back shares using some of the cash proceeds of the swap. Sanofi’s stock was up about 5.3 percent during morning trade on the Euronext Paris Stock Exchange. Boehringer is privately owned. The …
Sanofi-aventis' (NYSE: SNY) U.S. division announced that they would be streamlining their operations in lieu of the challenging healthcare marketplace. The restructuring will include an estimated 25% work force reduction in U.S. …
Sanofi India's net profit for the quarter ended December 31, 2013, witnessed over two-fold increase on account of robust sales in export markets. The company had posted a net profit of Rs 44.8 crore during the same period of the previous …
The pact does not cover chimeric antigen receptors, or CARs. Regeneron shares surged 2.4% in early trading today, with Sanofi's stock up a notch as well. Sanofi and Regeneron just made biotech history with a pioneering U.S. approval for …
Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations …
Sanofi India Ltd is currently trading at Rs. 4180, up by Rs. 18.6 or 0.45% from its previous closing of Rs. 4161.4 on the BSE. By clicking on submit button, you authorize IIFL & its representatives & agents to provide information about …
Its total revenue from operations stood at Rs667.5 crore in the third quarter, as compared with Rs638.2 crore in the year-ago period, Sanofi India said in a regulatory filing. The company’s stock ended 0.21% down at Rs4,199.25 on BSE.